Vaxart, Inc. (NASDAQ:VXRT) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET
Company Participants
Edward Berg – Senior Vice President and General Counsel
Steven Lo – Chief Executive Officer
James Cummings – Chief Medical Officer
Sean Tucker – Senior Vice President and Chief Scientific Officer
Phillip Lee – Chief Financial Officer
Conference Call Participants
Cheng Li – Oppenheimer
Mayank Mamtani – B. Riley Securities
Liang Cheng – Jefferies
Operator
Greetings and welcome to the Vaxart Business Update and Third Quarter 2024 Financial Results Conference Call. A question-and-answer session will follow management’s opening remarks. Individual investors may submit written questions to IR at vaxart.com. As a reminder, this conference is being recorded.
I would now like to turn the webcast over to your host Ed Berg, Senior Vice President and General Counsel.
Edward Berg
Good afternoon and welcome to today’s call. Joining us from Vaxart are Steven Lo, Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; Dr James Cummings, Chief Medical Officer; and Phil Lee, Chief Financial Officer.
Before we begin, I would like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company’s financial results, financial guidance, its future business strategies and operations, and its product development and regulatory progress, including statements about its ongoing or planned clinical trials.
Actual results could materially differ from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process and other risks described in the Risk Factors section of Vaxart’s most recently filed annual report on Form 10-K, and also on other periodic reports filed with the SEC. Vaxart undertakes no obligation to update any forward-looking statements after the date of this call.
I’ll now turn the call
Read the full article here
